It depends on the standard you follow. As of September 2026, Cencora, Inc. (COR) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and MSCI, and fails Dow Jones Islamic and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 17.9% / 30% · (Cash+Inv) / Mkt Cap (36m) 7.75% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 17.9% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 7.75% / 33% · Receivables / Mkt Cap (36m) 41.8% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 17.9% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 7.75% / 33.33% · Receivables / Mkt Cap (24m) 41.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 13.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 3.55% / 33.33% · Receivables / Avg Assets (4Q) 31.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 12.9% / 33.33% · (Cash+ST Inv) / Total Assets 5.60% / 33.33% · (Cash+Recv) / Total Assets 35.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Cencora, Inc. (COR) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and MSCI, and fails Dow Jones Islamic and FTSE.
Yes. Cencora, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Cencora, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q4 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Cencora, Inc. (NYSE: COR) is a Healthcare company (Medical - Distribution) with a market capitalization of $68.1B. The Maz Rating grades it against the other companies in its sector.
Cencora, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $356.94, Cencora, Inc. trades at 19.8x trailing earnings, 0.2x sales and 18.5x book value, with an EV/EBITDA of 12.1. Over the last twelve months it generated about $337.4B of revenue and $3.4B of net income. It runs a gross margin of 4.0%, an operating margin of 1.3% and a net margin of 1.0%. It shows return on equity of 115.8%, return on invested capital of 13.5% and a free cash flow yield of 5.7%. On the balance sheet: a debt-to-equity ratio of 3.06 and a current ratio of 0.94. Over the past 52 weeks the share price ranged from $244.82 to $377.54, with a beta of 0.58.
Cencora, Inc. pays a dividend yielding 0.69%, with 14% of earnings paid out. Its Maz Dividend Score is 3.03 out of 5, ranked against the other dividend payers in its sector (Safety 4.17, Growth 2.63, Yield 2.90, Consistency 1.31).
46 Wall Street analyst ratings cover the stock: 33 Buy, 12 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.